Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 178 of the 178 references it cites were found in a registry or an index.

The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease

Open access

Abstract

Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.

Overview

Integrity signals

Registry

Crossref · 10.1093/brain/awy132

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 178 references

Research works printed but not linked: 1

  1. Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263

Cited by

See all 1,918

Metadata

Authors
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Northwestern University (US)
  • McGill University (CA)
  • Indiana University School of Medicine (US)
  • University Hospital of Geneva (CH)
  • Saint Louis University (US)
  • Prevent Alzheimer’s Disease 2020 (US)
  • University of Rhode Island (US)
Corresponding author
Hampel, Harald
Venue
Brain
Published
2018-05-29
Volume
141
Issue
7
Pages
1917-1933
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2805257646
Cited by
1,918
References
178
Citations by year
2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
FWCI
14.70
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Purdue University Indianapolis (Indiana University) (submittedVersion)
Funders
  • AXA Research Fund
  • ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
  • ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
  • Canadian Institutes of Health Research
  • National Research Council
  • Alzheimer Society of Canada
  • Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
  • ADC (AG013854)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
MeSH terms
Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. https://app.cochat.ai/papers/10.1093/brain/awy132
The paper
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. https://doi.org/10.1093/brain/awy132

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.